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Background: Chemoresistance is a major obstacle in successfully treating cancers, and the mechanisms responsible
for drug resistance are still far from understood. Carbonic anhydrase 9 (CA9) has been shown to be upregulated in
the drug-resistant tongue cancer cell line Tca8113/PYM and to be associated with drug resistance. However, the
mechanisms regulating CA9 expression and its role in drug resistance remain unclear.
Methods: Bioinformatic and experimental analysis involving ChIP and luciferase reporter assays were used to
validate Zinc finger E-box-binding homeobox 1 (ZEB1) as a transcriptional regulator of CA9. Gene expression and
protein levels were evaluated by quantitative RT-PCR and western blotting, respectively. Sensitivity to chemotherapy
was examined using the MTS assay and Hoechst staining and analysis caspase-3 activity to evaluate changes in
apoptosis. Intracellular pH (pHi) was measured using fluorescent pH-indicator BCECF-AM. Protein expression in
patient tissue samples was examined by immunohistochemistry and survival of tongue cancer patients from
which these samples were derived was also analyzed.
Results: ZEB1 bound to the promoter of CA9 to positively regulate CA9 expression in tongue cancer cells.
Knockdown of CA9 using short interfering RNA (siRNA) abolished the chemoresistance resulting from ZEB1
overexpression in Tca8113 and SCC-25 cells, and CA9 overexpression attenuated chemosensitivity induced by
ZEB1 knockdown in Tca8113/PYM cells. CA9 knockdown also prevented maintenance of pHi mediated by
overexpression of ZEB1 in Tca8113 and SCC-25 cells following chemotherapy, associated with increased apoptosis
and caspase-3 activation. Conversely, ectopic expression of CA9 suppressed decrease in pHi mediated by ZEB1
knockdown in Tca8113/PYM cells following chemotherapy, accompanied by decreased apoptosis and caspase-3
activation. Importantly, a positive correlation was observed between ZEB1 and CA9 protein expression in tongue
cancer tissues, and expression of these proteins associated with a poor prognosis for patients.
Conclusion: Our finding that tumor cells regulate pHi in response to chemotherapy provides new insights into
mechanisms of drug resistance during cancer treatment. Identification of the ZEB1–CA9 signaling axis as a
biomarker of poor prognosis in tongue cancer will be valuable in future development of therapeutic strategies
aimed at improving treatment efficacy, especially in terms of drug resistance associated with this disease.
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Squamous cell carcinoma (SCC) of the oral cavity repre-
sents the tenth most frequent solid cancer worldwide [1].
Tongue cancer is the most common type of oral cancer
and frequently leads to the malfunction of mastication,
speech, and deglutition [2]. As one of the standard
therapeutic approaches, chemotherapy mostly based
on pingyangmycin (PYM) and/or cisplatin (cDDP),
plays an important role in tongue cancer treatment
and brings many benefits including reducing tumor
size, inhibiting distant metastasis and prolonging patient
survival [3]. However, resistance to anticancer agents is a
major obstacle for successful chemotherapy in tongue
cancer, as it can result in more aggressive tumor behavior
and worse clinical outcome [4,5]. The molecular basis of
sensitivity and resistance to chemotherapy is complex,
involving multiple biological processes such as drug
transport, drug metabolism, apoptosis and DNA repair
[6]. Although the mechanisms responsible for drug resist-
ance in cancer have been the subject of intense studies for
decades, the clinical causes of drug resistance remain
poorly understood. There is, therefore, an urgent need
to clarify these mechanisms and to explore alternative
therapeutic strategies to overcome drug resistance in
tongue cancer treatment.
We have previously shown that carbonic anhydrase IX
(CA9) expression is increased in the pingyangmycin
(PYM)-induced multidrug-resistant human tongue
squamous cell carcinoma cell line Tca8113/PYM when
compared to the parental cell line Tca8113, without
significant expression difference in multidrug resistance
genes such as MDR, BCRP and MRP. Functional experi-
ments demonstrated that both carbonic anhydrase inhibitor
application and knockdown of CA9 expression enhanced
PYM chemosensitivity [7]. In agreement with our previous
study, Michael et al. have suggested that CA9 expression in
squamous cell head and neck tumors is associated with
resistance to chemoradiotherapy [8]. CA9 overexpression
has been identified in a number of solid tumors, including
renal carcinomas, cervical squamous carcinomas, esopha-
geal carcinomas, bladder carcinomas and non-small cell
lung carcinomas. CA9 as a membrane-associated protein is
a zinc metalloenzyme catalyzing the reversible conversion
of CO2 to bicarbonate and a proton, and this has the effect
of reducing local extracellular pH [9]. Under equivalent
culture conditions, the extracellular pH (pHe) of the culture
media of Tca8113/PYM cells is much lower than that found
for the culture media of Tca8113 cells, and this can be
attributed to the increased expression of CA9 in the
Tca8113/PYM cell line [7]. Generally, solid cancers main-
tain a high intracellular pH (pHi) but a low extracellular
pH (pHe) that results from hypoxia or acidosis. Adaptation
of cancer cells to hypoxia and acidosis is a critical driving
force in tumor progression and metastasis [10,11]. Cancercells have developed key strategies to regulate their pHi,
because a pHi variation of as little as 0.1 can disrupt
multiple biological functions including ATP production,
protein synthesis, cell proliferation, migration and apoptosis
[12-14]. Whether cellular adaptation associated with drug
resistance is due to CA9 overexpression requires further
investigation. CA9 expression is strongly induced by
hypoxia-inducible factor 1 (HIF-1) and is believed to
be involved in cancer cell proliferation, transformation and
survival, making it a potential target for cancer therapy
[15,16]. However, there is no significant difference in the
expression of HIF-1 between Tca8113 and Tca8113/PYM
cells, implying some other factors are responsible for CA9
overexpression in Tca8113/PYM cells. In the present study,
we investigated the expression patterns of, and correlation
in expression between, CA9 and ZEB1 in tongue cancer
cell lines and tissues. Bioinformatics analysis combined
with experimental validation demonstrated that ZEB1
transcriptionally regulates CA9 expression and that
ZEB1 may contribute to chemotherapy resistance via
CA9-dependent modulation of pHi.
Results
ZEB1 transcriptionally regulates CA9 expression in tongue
cancer cells
We have previously shown that both CA9 mRNA and
protein expression is upregulated in the PYM-induced
multidrug-resistant tongue cancer cell line Tca8113/PYM.
To determine whether transcriptional regulation contributes
to CA9 upregulation in Tca8113/PYM cells, we analyzed
the response elements of a cohort of transcription factors
located within a three kilobase region upstream of the first
exon of the CA9 gene. Using the JASPAR database
(http://jaspar.binf.ku.dk) we identified five putative
ZEB1 binding sites within this region, conforming to
the optimal recognition sequence of ZEB1 (CACCTG)
(Figure 1A). To confirm the direct association of
ZEB1 with the CA9 promoter, we performed a ChIP assay
in Tca8113/PYM cells for all putative ZEB1 binding sites
within the three kilobase region. ChIP results revealed that
ZEB1 bound most significantly to sites B, C and E within
the potential CA9 promoter (Figure 1B). As expected,
ectopic expression of ZEB1 using the pLEX-ZEB1 con-
struct enhanced both CA9 mRNA and protein expression
in Tca8113 and SCC-25 cell lines (Figure 1C and D).
Conversely, CA9 mRNA and protein expression decreased
following knockdown of ZEB1 in Tca8113/PYM cells
using ZEB1-specific siRNAs (Figure 1C and D). To inves-
tigate further the effects of ZEB1 on CA9 expression,
the putative three kilobase CA9 promoter was cloned
into a luciferase reporter vector and expression assays
subsequently performed. As expected, CA9 promoter-
driven luciferase activity was much higher in Tca8113/PYM
cells than in Tca8113 and SCC-25 cells (Figure 1E). In
Figure 1 CA9 is upregulated by ZEB1 in tongue cancer cells. (A) A schematic representation of ZEB1 binding sites with the E-box sequence
(CACCTG) in the 3kb putative CA9 promoter. The first base of the 3kb strand is defined as ‘1’. (B) Chromatin immunoprecipitation assays
identified ZEB1 binding sites within the putative CA9 promoter. Primers specific for sites B, C and E yielded PCR reaction products from
ZEB1–DNA immunoprecipitates. The input represents DNA directly after lysis. The PCR reaction product for immunoprecipitates obtained
using the RNA Polymerase antibody represents the positive control. (C and D) Changes in CA9 mRNA and protein expression following
the inhibition of ZEB1 in tongue cancer cell lines were evaluated by qRT-PCR and western blotting, respectively. (E) Luciferase activity driven by the
putative CA9 promoter was higher in Tca8113/PYM cells (which exhibit endogenous ZEB1 overexpression) than in Tca8113 and SCC-25 cells.
(F) Reporter assays revealed changes in luciferase activity after inhibition of ZEB1 expression in tongue cancer cells. (G) ZEB1 promoted luciferase
activity driven by the putative CA9 promoter in HEK283T cells. * p < 0.01.
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erase activity driven by the CA9 promoter in HEK293T
cells (Figure 1G). These results demonstrate that ZEB1
can directly bind to the CA9 promoter to transcriptionally
regulate CA9 expression.
CA9 contributes to ZEB1-mediated drug resistance in
tongue cancer cells
We have previously shown that CA9 is involved in drug
resistance in tongue cancer cells, and have shown herethat ZEB1 positively regulates CA9 expression. Next, we
wished to determine whether ZEB1 modulates chemosen-
sitivity in tongue cancer and whether it exerts its effect via
regulating CA9 expression. We found that ectopic ZEB1
expression enhanced the resistance of Tca8113 and SCC-
25 cells to PYM or cDDP, with the marked increase of
IC50 values (Figure 2A and B). Conversely, ZEB1 knock-
down increased the sensitivity of Tca8113/PYM cells to
PYM and cDDP, with the significant decrease of IC50
values (Figure 2C). Moreover, CA9 knockdown markedly
Figure 2 The ZEB1–CA9 axis regulates chemosensitivity in tongue cancer cells. (A and B) MTS cell proliferation assays showed that ZEB1
overexpression promoted resistance in Tca8113 and SSC-25 cells in response to PYM and cDDP, and that knockdown of CA9 abolished this effect.
(C) Knockdown of ZEB1 enhanced the sensitivity of Tca8113/PYM cells to PYM and cDDP, while overexpression of CA9 attenuated this effect. * p < 0.01.
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in Tca8113 and SCC-25 cells (Figure 2A and B), while
overexpression of CA9 in Tca8113/PYM cells impaired the
effect of ZEB1 knockdown in response to chemotherapy
(Figure 2C), suggesting CA9 is responsible for ZEB1-
mediated drug resistance in tongue cancer cells.
The ZEB1–CA9 axis regulates chemotherapy-induced
changes in intracellular pH
Tumor cells usually have a higher pHi (which is neutral-
to-alkaline) in comparison to normal cells [17]. Alterations
in pHi homeostasis have been implicated in anticancer
drug treatment and drug-resistant cancer cells may develop
multiple mechanisms to regulate pHi more effectively inresponse to extracellular or intracellular stress. Here,
we found that PYM (80mg/L) or cDDP (5mg/L) treat-
ment resulted in a significant decrease in the pHi
(Figure 3A and C) and an accompanying increase in
apoptosis (Figure 3B and D) in Tca8113 and SCC-25
cells when compared to Tca8113/PYM cells (Figure 3E
and F). Ectopic ZEB1 expression markedly impaired
the PYM or cDDP-induced decrease in pHi and the
associated increase in apoptosis in Tca8113 and SCC-25
cell lines (Figure 3A–D). However, knockdown of CA9 in
these cells attenuated the effect of ectopic ZEB1 expression
on pHi and apoptosis following PYM or cDDP treatment
(Figure 3A–D). Moreover, in Tca8113/PYM cells, knock-
down of ZEB1 enhanced the PYM or cDDP-dependent
Figure 3 (See legend on next page.)
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Figure 3 The ZEB1–CA9 axis prevents pHi decrease induced by chemotherapy in tongue cancer cells. (A, C and E) The change in pHi found
for each given cell line in response to PYM or cDDP treatment, as determined using the BCECF-AM pH fluorescence probe in conjunction with
confocal microscopy. (B, D and F) Changes in apoptosis in response to PYM or cDDP treatment for each given cell line, as determined by Hoechst
staining evaluated by fluorescence microscopy. * p < 0.01.
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while overexpression of CA9 essentially abolished
these effects (Figure 3E and F). These findings suggest
that the ZEB1–CA9 signaling axis prevents pHi decrease
and apoptosis induced by chemotherapy.
The ZEB1–CA9 axis modulates chemotherapy-induced
caspase-3 activation
A decrease in pHi correlates with an increase in apoptosis
and caspase-3 is a key component of the apoptotic pathway
[18]. We therefore performed a caspase-3 activity assay and
western blotting to detect the cleaved, active protein and
therefore determine the functional state of caspase-3 in
cultured cells. We found that PYM (80mg/L) or cDDP
(5mg/L) treatment significantly promoted caspase-3 acti-
vation in Tca8113 and SCC-25 cells (Figure 4A and B)
and this was accompanied by a decrease in pHi (Figure 3A
and B). With respect to the change in pHi, we found that
ectopic ZEB1 expression blocked PYM or cDDP-induced
caspase-3 activation in Tca8113 and SCC-25 cells
(Figure 4A and B), while the simultaneous knockdown of
CA9 abolished this ZEB1-related effect (Figure 4A and B).
Furthermore, in Tca8113/PYM cells (in which endogenous
ZEB1 is upregulated) we found that knockdown of ZEB1
promoted caspase-3 activation in response to PYM or
cDDP (Figure 4C). However, ectopic CA9 expression atten-
uated the effect of ZEB1 knockdown on caspase-3 activa-
tion (Figure 4C). These results suggest that CA9 is involved
in the ZEB1-dependent inhibition of caspase-3 activation.
ZEB1 and CA9 are negative prognostic markers in
tongue cancer
Given the above observations in cultured cells, namely
that ZEB1 transcriptionally regulates CA9 expression
and that the ZEB1–CA9 axis mediates chemotherapy
resistance, we next wished to assess whether there is a
correlation between ZEB1 expression and CA9 expression
in tongue cancer. We therefore performed immunohisto-
chemical staining on tissue arrays containing tongue cancer
tissue from 84 patients receiving chemotherapy based on
PYM and/or cDDP. Notably, CA9 protein was strongly
expressed in 39 of 41 tongue cancer tissues that exhibited
high ZEB1 protein expression (Figure 5A). In contrast,
CA9 protein was strongly expressed in only 8 of 43 tongue
cancer tissues that exhibited low ZEB1 protein expression
(Figure 5A). Importantly, tongue cancer patients with high
ZEB1 expression have a poor prognosis for overall survival
compared to patients with low ZEB1 expression (Figure 5B).In addition, high CA9 expression was also predictive
of worse overall survival for tongue cancer patients
(Figure 5B). Moreover, tongue cancer patients with
both high ZEB1 and CA9 expression have worse overall
survival compared to patients with both low ZEB1 and
CA9 expression (Figure 5B). All the results denoted a
potential correlation between ZEB1 and CA9 expression
and their indication for the poor prognosis in human
tongue cancer patients.
Discussion
Therapeutic resistance, which often appears and which is
caused by various mechanisms, is the central problem in
cancer therapy [19]. This underlines the critical importance
of elucidating the precise molecular mechanisms involved
in the anticancer drug resistance of cancer cells for
improving current treatments in the clinic. We have
previously shown that overexpression of CA9 is associated
with drug resistance in tongue cancer cells [7], although
at that time the mechanism of CA9 upregulation was
unclear. In the present study, bioinformatics analysis
combined with experimental validation has revealed
that ZEB1 binds to the promoter of the CA9 gene
and positively regulates its activity. ZEB1 expression
was also found to promote CA9 expression in tongue
cancer cells. Given the role of CA9 in drug resistance
and that ZEB1 regulates the expression of CA9, we further
investigated the role of ZEB1 in the drug resistance of
tongue cancer cells. We found that ectopic expression of
ZEB1 in tongue cancer cells significantly enhanced
their resistance to chemotherapy while knockdown of
ZEB1, conversely, increased sensitivity to chemotherapy.
Moreover, knockdown of CA9 attenuated the effect of
ectopic ZEB1 expression on the chemosensitivity of
Tca8113 and SCC-25 cell lines and ectopic CA9 expression
abolished the effect of ZEB1 knockdown on chemoresistant
Tca8113/PYM cells.
ZEB1 has been reported to be highly expressed in
epithelial cancers and its expression correlates with
poor prognosis [20]. ZEB1 is a known driver of epithelial-
to-mesenchymal transition (EMT), a phenotype associated
with cancer cells that are typically prone to metastasis,
drug resistance and poor clinical outcome, and which rep-
resent potential therapeutic targets for cancer progression.
ZEB1 represses the expression of epithelial genes and
certain micro RNAs (miRNAs), including the miR-183,
miR-203 and miR-200 family members, which function
not only as strong inducers of EMT but also as inhibitors
Figure 4 (See legend on next page.)
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Figure 4 ZEB1–CA9 prevents chemotherapy-induced caspase-3 activation. (A and B) PYM and cDDP induced caspase-3 activation in Tca8113
and SCC-25 cell lines, respectively, as measured by reporter assays and western blotting. Overexpression of ZEB1 prevented caspase-3 activation
in response to chemotherapy, while knockdown of CA9 impaired the effects of ZEB1 overexpression. (C) Chemotherapy had no significant effect
on caspase-3 activation in Tca8113/PYM cells. Knockdown of ZEB1 enhanced caspase-3 activation induced by chemotherapy, and overexpression
of CA9 attenuated this effect. vs. no treatment, * p < 0.01.
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the EMT phenotype, inhibits migratory ability and en-
hances the chemosensitivity of docetaxel-resistant human
lung adenocarcinoma cells [23]. The ZEB1 pathway links
glioblastoma initiation and invasion. ZEB1 expression in
glioblastoma patients is predictive of shorter survival and
poor temozolomide response [24]. Moreover, ZEB1 has also
been reported to be closely associated with radioresistance
[25,26]. We now show here that ZEB1 predominantly
correlates with drug resistance, mainly via modulating CA9
expression in tongue cancer cells.Figure 5 ZEB1 expression correlates with that of CA9 in tongue cancer an
of ZEB1 and CA9 protein expression in tongue cancer tissues. ZEB1 protein
of CA9 protein expression in tongue cancer tissues that exhibit different le
estimated overall survival according to the ZEB1 protein level, CA9 proteinCA9 has been reported to be overexpressed in many
types of solid tumors and contributes to low pHe [9], as
observed in our experimental model [7]. The cancer
cells of solid tumors usually developed the ability to
maintain a high pHi and a low pHe to adapt and sustain
normal biological process, as intracellular acidification is
closely associated with apoptosis. A change of pHi/pHe
ratio of 0.1-0.2 pH units can have disastrous consequences
for critical biological processes including ATP synthesis,
proliferation, metastasis and survival [27-29]. Nitric oxide-
induced acidification drives nitric oxide-induced apoptosisd is associated with poor clinical prognosis. (A) Representative images
expression was positively correlated with that of CA9 (left). The level
vels of ZEB1 protein expression (right). (B) Kaplan–Meier analysis
level, and both ZEB1 and CA9 protein levels.
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leukemic cell lines and peripheral blood from primary
patient leukemic samples exhibited a constitutively higher
pHi than normal hematopoietic tissue, and that a pHi
decrease enhanced apoptosis in leukemic cells [18].
Caspase activation plays a critical role during apoptosis.
The efficiency of caspase activation by cytochrome C is
pH-sensitive, and lower pH drives this activation [31].
With respect to CA9, Chiche et al. have shown that forced
expression of CA9 contributes to extracellular acidifica-
tion and to the maintenance of a more alkaline pHi [32].
The primary enzymatic function of CA9 is to catalyze the
reversible hydration of carbon dioxide to bicarbonate and
protons to contribute to acidification of the tumor micro-
environment, acting as a “catalytic converter” for the ex-
cretion of acid from cells. Bicarbonate is shuttled into the
cytoplasm to buffer pHi, while the proton remains in the
extracellular space. The biological effects of CA9 help to
produce and maintain an alkaline pHi favorable for tumor
growth, and participate in the generation of an increas-
ingly acidic extracellular space, facilitating tumor progres-
sion. Thus, Inhibition of CA9 interferes with removal of
acid and results in a decrease in pHi, negatively influen-
cing cell survival [33,34]. In our study here we performed
a series of experiments to determine whether ZEB1–CA9
mediates drug resistance via maintaining the pHi. We
found that the pHi in chemo-sensitive Tca8113 and SCC-
25 cells rapidly decreased upon treatment with PYM or
cDDP, whereas this was not observed for chemoresistant
Tca8113/PYM cells. However, overexpression of ZEB1 pre-
vented both the pHi decrease and caspase-3 activation
induced by chemotherapy, and knockdown of CA9
abolished the effect of ZEB1 overexpression on Tca8113
and SCC-25 cells. In multidrug-resistant Tca8113/PYM
cells, knockdown of ZEB1 promoted a decrease in pHi after
exposure to PYM or cDDP, but this decrease was blocked
following CA9 overexpression. Importantly, we found that
ZEB1 protein expression strongly correlated with CA9
protein expression, and that the ZEB1–CA9 axis was a
negative prognostic factor for overall survival in tongue
cancer patients. Therefore, ZEB1 transcriptionally regulates
CA9 expression to mediate chemoresistance in tongue
cancer via modulating pHi in response to chemotherapy.
Further study will now be required to elucidate the molecu-
lar mechanisms coupling ZEB1–CA9 to changes in pHi and
the response to chemotherapy, and to determine whether
observations made in vitro are reflected in the clinic. In
addition, new strategies should be developed to enable the
monitoring of these biochemical changes in response to
chemotherapeutic agents both in vitro and in vivo.
Conclusion
In our present study, we elucidated the mechanisms
responsible for the regulation of CA9 expression, and haveidentified the ZEB1–CA9 axis as a mediator of resistance
to chemotherapy. ZEB1–CA9 mediates chemoresistance
mainly via maintaining the pHi in response to chemo-
therapy, providing new insights into the complex
mechanisms of drug resistance. Our findings strongly
suggest that the ZEB1–CA9 axis can be a prognostic bio-
marker for tongue cancer patients and provides a rationale
for the development of anticancer intervention strategies
targeting the ZEB1–CA9 axis in clinics.
Materials and methods
Cell culture and tissue specimens
The human tongue squamous cell carcinoma cell line
Tca8113 derived from moderately differentiated human
tongue squamous cell carcinoma and the stable
PYM-resistant cell line Tca8113/PYM, and squamous
cell carcinoma cell line SCC-25 from American Type
Culture Collection, were cultured in RPMI-1640 (Gibco)
containing 10% fetal bovine serum (Gibco) at 37°C in a
humidified atmosphere containing 5% CO2. To maintain
the resistance phenotype, 0.5mg/L PYM was added to the
culture media of Tca8113/PYM cells. The HEK293T
human embryonic kidney cell line was cultured in DMEM
(Gibco) with 10% fetal bovine serum. Eighty-four tongue
cancer tissue specimens were obtained from patients at
the Affiliated Tumor Hospital of Guangzhou Medical
University between March 2000–December 2006. Overall
survival was computed from the day of surgery to the day
of death or of last follow-up. The study was approved by
the ethics committee of the Affiliated Tumor Hospital of
Guangzhou Medical University.
ChIP assay
The ChIP assay was performed using the EZ-CHIP™
chromatin immunoprecipitation kit (Merck Millipore).
Briefly: Chromatin proteins were cross-linked to DNA
by addition of formaldehyde to the culture medium to a
final concentration of 1%. After a 10 min incubation at
room temperature, the cells were washed and scraped
off in ice-cold phosphate-buffered saline (PBS) containing
Protease Inhibitor Cocktail II. Cells were pelleted and then
resuspended in lysis buffer containing Protease Inhibitor
Cocktail II. The resulting lysate was subjected to sonication
to reduce the size of DNA to approximately 200–1000 base
pairs in length. The sample was centrifuged to remove
cell debris and diluted ten-fold in ChIP dilution buffer
containing Protease Inhibitor Cocktail II. A 5 μl sample of
the supernatant was retained as “Input” and stored at 4°C.
Then 5 μg of anti-RNA Polymerase antibody (positive
control, included with the kit), or anti-ZEB1 antibody (cell
signal technology) were added to the chromatin solution
and incubated overnight at 4°C with rotation. After anti-
body incubation, protein G agarose was added and the
sample incubated at 4°C with rotation for an additional 2
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Buffers four times and eluted with ChIP Elution Buffer.
Cross-links were then reversed to free DNA by the
addition of 5M NaCl and incubation at 65°C for 4 h.
The DNA was purified according to the manufacturer’s
instructions. 50 μl of DNA was obtained for each
treatment. 0.2 μl of DNA from each group was used as a
template for PCR. Primers for the CA9 promoter containing
putative ZEB1 binding sites were as follows, sense: 5′-
TGTTGGCCAGGCTGGTCT-3′, antisense: 5′-CCACTT
GAGTGCCTCAGCCA-3′ (for site A); sense: 5′-GTAGTA
TACCAGTCAGGTGTC-3′, antisense: 5′-AGAGATGGG
ATCTCACTGTGTT-3′ (for site B); sense: 5′-CAGTCTC
AGCTCACTGCAGC-3′, antisense: 5′-GTGGGTGGTTG
CTTGAGTCCAG-3′ (for site C); sense: 5′-CTGACACAT
ACACTTGCTTTTC-3′, antisense: 5′-TGGCTGAGAGG
GAAAGCAGCTC-3′ (for site D); sense: 5′-CCTGCA
TAGTGCCAGGTGG-3′, antisense: 5′-GAGATGGAGC
CAAAGTCTCACAG-3′ (for site E). Primers for the
human GAPDH gene: sense, 5′-TACTAGCGGTTT
TACGGGCG-3′, antisense, 5′-TCGAACAGGAGGAGCA
GAGAGCGA-3′. The PCR conditions were as follows: 1
cycle of 95°C for 5 min; 32 cycles of 95°C for 20 s, 59°C for
30 s, and 72°C 30 s; and 1 cycle of 72°C for 10 min. PCR
samples were resolved by electrophoresis in a 2% agarose
gel and stained with ethidium bromide.
Cells transfection
Cells were trypsinized, counted and seeded into six-well
plates the day before transfection to ensure 70% cell
confluency on the day of transfection. The transfection
of the pLEX-ZEB1 vector, the pLEX-CA9 vector and
related controls was carried out using Lipofectamine
2000 (Invitrogen) in accordance with the manufacturer’s
instructions. siRNAs targeting ZEB1 or CA9 and siRNA
controls were purchased from Santa Cruz Biotechnology.
Transfection of siRNA (50 nM final concentration) was
performed as above. Experiments were performed 48 h
post-transfection.
Real-time PCR
Total RNA was extracted using Trizol, and cDNAs
subsequently synthesized from mRNA templates using
the Super-Script first-strand synthesis system (Thermo
Scientific). Real-time PCR was carried out according
to standard protocols using an ABI 7500 with SYBR Green
detection (Applied Biosystems). GAPDH was used as an
internal control and the qRT-PCR was repeated three
times. The primers for GAPDH were: forward primer
5′-ATTCCATGGCACCGTCAAGGCTGA-3′, reverse pri-
mer 5′-TTCTCCATGGTGGTGAAGACGCCA-3′; primers
for CA9 were: forward primer 5′- GTCCAGCTGAATTC
CTGCCT-3′, reverse primer 5′-CCTTCTGTGCTGCCT
TCTCA-3′.Western blotting
Total protein was extracted from cells using RIPA buffer
(Pierce) in the presence of protease inhibitors (Protease
Inhibitor Cocktail, Pierce). The protein concentration of
lysates was measured using a BCA Protein Assay Kit
(Pierce). Equivalent amounts of protein were mixed with
5 × Lane Marker Reducing Sample Buffer (Pierce), and
resolved by electrophoresis in a 10% SDS–polyacrylamide
gel and then transferred onto Immobilon-P Transfer
Membrane (Millipore). The membranes were blocked
with 5% non-fat milk in Tris-buffered saline and then
incubated with primary antibodies followed by secondary
antibody. The signal was detected on the Odyssey instru-
ment (LI-COR Bioscience). ZEB1, CA9, Caspase-3, and
β-Actin antibodies were from Cell Signaling Technology,
and the fluorescently labeled secondary antibodies were
from LI-COR Bioscience.
Promoter activity analysis
To determine whether ZEB1 regulates the promoter
activity of CA9, a three kilobase region upstream of the
first exon of CA9 was cloned into the pGL4-reporter
vector upstream of the luciferase gene. Cells were seeded in
96-well plates and co-transfected with the pGL4-reporter
vector and the pRL-TK Renilla luciferase vector with or
without the pLEX-ZEB1 vector using Lipofectamine 2000
(Invitrogen). After 48 h, luciferase activity was determined
using a Dual-Luciferase Reporter Assay System (Promega)
on the BioTek Synergy 2. Renilla luciferase activity was
used as an internal control and the firefly luciferase activity
was calculated as the mean +/- standard deviation after
normalization relative to the Renilla luciferase activity.
Cell proliferation assays (MTS)
The CellTiter 96 AQueous One Solution Cell Proliferation
Assay kit (Promega, Madison, WI, USA) was used to
determine the sensitivity of cells to PYM or cDDP.
Briefly, cells were seeded in 96-well plates at a density
of 4 × 103 cells/well (0.2 ml/well) for 24 h before use.
The culture medium was replaced with fresh medium
containing PYM or cDDP at different concentrations
and cells were then incubated for a further 72 h. Then,
MTS (0.02 ml/well) was added. After a further 2 h incuba-
tion, the absorbance at 490 nm was recorded for each well
on the BioTek Synergy 2. The absorbance represented the
cell number and was used for the plotting of dose–cell
number curves.
Intracellular pH (pHi) measurement
The pHi of cells was measured using the fluorescent pH-
indicator 2,7-bicarboxyethyl-5,6-carboxyfluorescein-acet-
oxymethylester (BCECF-AM) (Molecular Probes, Eugene,
OR, USA) following the manufacturer’s protocol. BCECF is
a neutral lipophilic form of bis-carboxyfluorescein which
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cell it is hydrolyzed by esterases, releasing BCECF which is
retained within the cytoplasm. The fluorescence intensity
of BCECF is dependent upon pH. After an incubation
of 10 min, the fluorescence intensity was measured using
confocal microscopy using an excitation wavelength
of 535 nm.Hoechst staining
Following transfection cells were reseeded in fresh
medium in 24-well plates. After a 24 h incubation, cells
were treated with or without PYM (80mg/L) or cDDP
(5mg/L) for an additional 48 h. The cells were then
stained with hoechst33528, and apoptotic cells possessing
significantly smaller, condensed and fragmented nuclei,
were observed using a fluorescence microscope. The
apoptotic cell number was determined for at least three
fields-of-view for each treatment and the apoptotic rate
then calculated.Caspase-3 activity assay
Caspase-3 activity was determined using a caspase-3
activity kit (Beyotime), in which cleavage of a colorless
substrate specific for caspase-3 [Ac-DEVD-p-nitroaniline
(pNA)], releases the chromophore pNA. Assays were
carried out according to the manufacturer’s instruc-
tions. To evaluate the activity of caspase-3, lysates
were prepared from cells after their respective treat-
ments. Assays were performed in 96-well microtiter
plates. Briefly; for each sample 10 μl of cell lysate was
combined with 80 μl of reaction buffer and 10 μl of
caspase-3 substrate (Ac-DEVD-pNA, 2mm). Lysates were
then incubated at 37°C for 4 h and samples subse-
quently measured on the BioTek Synergy 2 system using
an absorbance of 405 nm.Immunohistochemistry
A tissue array containing 84 human tongue cancer
specimens was cut into 4-μm sections. The sections
were dried at 62°C for 2 h and then deparaffinized in
xylene and rehydrated using a series of graded alcohol
washes. The tissue slides were then treated with 3%
hydrogen peroxide in methanol for 15 min to quench
endogenous peroxidase activity, and antigen retrieval
then performed by incubation in 0.01 M sodium cirate
buffer (pH 6.0) and heating using a microwave oven. After
a 1 h preincubation in 10% goat serum, the specimens
were incubated with primary antibody overnight at 4°C.
The tissue slides were treated with a non-biotin horserad-
ish peroxidase detection system according to the manufac-
turer’s instruction (DAKO). Two different pathologists
evaluated the immunohistological samples.Statistical analysis
All statistical analyses were performed with SPSS statistical
software (version 21.0; IBM). Survival curves were con-
structed using the Kaplan–Meier method and analyzed by
the log-rank test. Significant prognostic factors identified
by univariate analysis were entered into multivariate
analysis using the Cox proportional hazards model. The
Student’s t-test was used for comparisons and the Pearson
correlation test (two-tailed) was used to investigate the
correlation between ZEB1 and CA9 protein levels.
Statistical significance was defined as P < 0.05.
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